La maladie du greffon contre l’hôte, graft-versus-host disease, une complication exceptionnelle de la transplantation pulmonaire

Morisse-Pradier, H.; Nové-Josserand, Raphaële; Philit, F.; Sénéchal, Agathe; Berger, Françoise; Callet‐Bauchu, Evelyne; Traverse-Gléhen, Alexandra; Maury, Jean‐Michel; Grima, Renaud; Tronc, François; Mornex, Jean‐François

doi:10.1016/j.pneumo.2015.05.004

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, patients whose immune systems are suppressed and receive white blood cells from another individual are at high risk of developing the disease. However, GVHD can seldom develop in various clinical settings other than HSCT, such as solid organ transplantation when T cells within the donor's tissues are not eliminated, or after transfusion of blood products (post-transfusion GVHD) (22)(23)(24).…”

Section: Introductionmentioning

confidence: 99%

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies

et al. 2020

View full text Add to dashboard Cite

Graft versus host disease (GVHD) is one of the main causes of mortality and the reason for up to 50% of morbidity after hematopoietic stem cell transplantations (HSCT) which is the treatment of choice for many blood malignancies. Thanks to years of research and exploration, we have acquired a profound understanding of the pathophysiology and immunopathology of these disorders. This led to the proposition and development of many therapeutic approaches during the last decades, some of them with very promising results. In this review, we have focused on the recent GVHD treatments from classical chemical and pharmacological prophylaxis to more innovative treatments including gene therapy and cell therapy, most commonly based on the application of a variety of immunomodulatory cells. Furthermore, we have discussed the advantages and potentials of cell-free therapy as a newly emerging approach to treat GVHD. Among them, we have particularly focused on the implication of the TNFα-TNFR2 axis as a new immune checkpoint signaling pathway controlling different aspects of many immunoregulatory cells.

show abstract

Section: Introductionmentioning

confidence: 99%